<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SHPGY</title>
	<atom:link href="http://www.stockbloghub.com/tag/shpgy/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SHPGY) Shire and Sangamo BioSciences Cut a Deal</title>
		<link>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440</link>
		<comments>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440#comments</comments>
		<pubDate>Tue, 14 Feb 2012 15:22:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sangamo Biosciences Inc]]></category>
		<category><![CDATA[SGMO]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91440</guid>
		<description><![CDATA[Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development of products for hemophilia and other monogenic diseases. These products will be developed using Sangamo’s zinc finger DNA-binding protein (”ZFP”) technology. Terms of the Deal Shire will make an upfront payment of $13 million to Sangamo. Sangamo will also be eligible to receive milestone payments of up to $213.5 million based on the achievement of research, regulatory, development and commercial targets. Shire will pay Sangamo tiered double-digit royalties on product sales. As per the agreement, Shire will get exclusive global rights to ZFP therapeutics designed to target 4 genes for investigating curative therapies for hemophilia A and B. Shire also gets the right to designate 3 additional gene targets. While Sangamo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/14/shpgy-shire-and-sangamo-biosciences-cut-a-deal/91440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BGC) Company News for August 3, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511#comments</comments>
		<pubDate>Wed, 03 Aug 2011 15:33:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Industrial Electrical Equipment]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[BGC]]></category>
		<category><![CDATA[Foster Wheeler AG]]></category>
		<category><![CDATA[FWLT]]></category>
		<category><![CDATA[General Cable Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Herbalife Limited]]></category>
		<category><![CDATA[HLF]]></category>
		<category><![CDATA[II-VI Inc]]></category>
		<category><![CDATA[IIVI]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[Westlake Chemical Corporation]]></category>
		<category><![CDATA[WLK]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80511</guid>
		<description><![CDATA[•    Westlake Chemical Corporation (NYSE:WLK) posted Q2 EPS of $1.21, beating analysts’ estimates of $1.19 per share. Revenues rose 13% year-over-year to $925.0 million •    Engineering company Foster Wheeler AG’s (NASDAQ:FWLT) shares rose 2.12% to close at $27.02 after the company posted second-quarter earnings that came in above the Street&#8217;s expectations •    Share prices of Herbalife Ltd. (NYSE:HLF) increased 5.69% after the nutritional-supplement seller forecasted third-quarter earnings beating analysts’ estimates •    Pfizer (NYSE:PFE) reported adjusted Q2 EPS of $0.60, marginally ahead of the Zacks Consensus Estimate of $0.59 per share. Revenues for the quarter fell 1% to $17.0 billion, in line with the Zacks Consensus Estimate •    General Cable Corp.’s  (NYSE:BGC) share prices declined by 17.67% after the wire maker&#8217;s second quarter profit and revenue figures came in behind estimates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bgc-company-news-for-august-3-2011-corporate-summary/80511/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658</link>
		<comments>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658#comments</comments>
		<pubDate>Fri, 08 Jul 2011 20:49:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78658</guid>
		<description><![CDATA[The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years and adults. The lawsuit comes in response to the  abbreviated new drug application (ANDA) filed by Watson Pharma with the US Food and Drug Administration (FDA) to market a generic version of Vyvanse. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing a patent infringement lawsuit, Shire has ensured a 30-month stay by the FDA. Consequently, the ANDA cannot be cleared by the regulatory body before August 23, 2014 or until a court ruling, whichever ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527</link>
		<comments>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527#comments</comments>
		<pubDate>Thu, 07 Jul 2011 16:59:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78527</guid>
		<description><![CDATA[The legal tussle between Shire (SHPGY), Sandoz, Inc. &#8212; the generic arm of Novartis (NVS) and Amneal Pharmaceuticals &#8212; intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). Amneal and Sandoz have filed abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of Vyvanse at all doses. ADHD refers to a neurobiological disorder that is often hereditary in nature. The disease gives way to lack of attention and often results in impulsiveness and hyperactivity. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing patent infringement lawsuits Shire has ensured a 30-month stay by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768</link>
		<comments>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:43:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77768</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. The phase II BEAM study was conducted in patients with moderate to severe chronic kidney disease and type II diabetes. Results showed that patients receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period as measured by estimated glomerular filtration rate (eGFR), which is an important measure of kidney function. All three doses (25, 75 or 150 mg) of bardoxolone methyl achieved a statistically significant improvement in eGFR compared to placebo. Moreover, only 9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/abt-abbott-labs-and-reata-pharmaceuticals-present-new-phase-ii-data/77768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire to Produce More Replagal</title>
		<link>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664</link>
		<comments>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664#comments</comments>
		<pubDate>Tue, 28 Jun 2011 15:54:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[HGT]]></category>
		<category><![CDATA[Hugoton Royalty Trust]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77664</guid>
		<description><![CDATA[UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved for treating Fabry disease. The EMA declared that Replagal can be purified at its new manufacturing facility located in Lexington. The European approval for the new manufacturing facility for Replagal was sought by Shire in April 2011. The approval grants Shire, the global market leader for the treatment of Fabry disease, an additional manufacturing facility to purify the product. Prior to the approval, Replagal was purified only at the company’s facility in Alewife, Cambridge. The increased manufacturing strength will enable Shire meet the huge demand for treating the disease in a more efficient manner. Shire’s Replagal competes with Sanofi-Aventis’ (SNY) Fabrazyme in the market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/28/shpgy-shire-to-produce-more-replagal/77664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire&#8217;s Firazyr Earns FDA Panel Backing</title>
		<link>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456</link>
		<comments>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456#comments</comments>
		<pubDate>Sun, 26 Jun 2011 17:48:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77456</guid>
		<description><![CDATA[Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant). Shire is looking to get Firazyr approved in the US for treating patients (aged 18 years and above) suffering from acute attacks of hereditary angioedema (HAE). HAE is a rare genetic disease characterized by acute swelling of the hands, feet, face and larynx. The FDA panel was convinced of Firazyr’s safety and effectiveness based on data from three double-blind, randomized late-stage studies (FAST-1, FAST-2, and FAST-3). Twelve of the 13 members of the panel recommended the approval of the drug for the indication. Moreover, 11 of the 13 members (one member voted against the motion while the other panel member abstained from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/26/shpgy-shires-firazyr-earns-fda-panel-backing/77456/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs&#8217; Bardoxolone in Phase III Trials</title>
		<link>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721</link>
		<comments>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:25:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Marshall & Ilsley Corporation]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76721</guid>
		<description><![CDATA[Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational, double-blind, placebo-controlled phase III study, BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), will be conducted with about 1,600 patients across 300 sites. Patients will be randomized 1:1 to receive either a 20 mg reformulated version of bardoxolone methyl or placebo once daily. While the primary efficacy endpoint is a time-to-first-event composite consisting of progression to end-stage renal disease (ESRD) and cardiovascular death, secondary endpoints include change in estimated glomerular filtration rate (eGFR) and a time-to-first-event composite consisting of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/abt-abbott-labs-bardoxolone-in-phase-iii-trials/76721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Acquires Genzyme &#8211; Acquisition to Create New Source of Growth at Sanofi</title>
		<link>http://www.stockbloghub.com/2011/04/12/sny-sanofi-aventis-acquires-genzyme-acquisition-to-create-new-source-of-growth-at-sanofi/71232</link>
		<comments>http://www.stockbloghub.com/2011/04/12/sny-sanofi-aventis-acquires-genzyme-acquisition-to-create-new-source-of-growth-at-sanofi/71232#comments</comments>
		<pubDate>Tue, 12 Apr 2011 21:00:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71232</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) recently completed its acquisition of biotech company Genzyme Corporation. With the completion of the acquisition, Genzyme, now a wholly-owned subsidiary of Sanofi, will be Sanofi’s global center for excellence in rare diseases. Sanofi said that 237,312,826 shares of Genzyme were validly tendered, representing about 89.4% of Genzyme&#8217;s outstanding shares. As a reminder, per the terms of the deal announced in Feb 2011, Genzyme shareholders received $74 per share in cash (or $20.1 billion) in addition to a contingent value right (CVR) for each share. The CVR allows each shareholder to receive additional payments related to Lemtrada (alemtuzumab for multiple sclerosis) and the achievement of specified production volumes in 2011 for Cerezyme and Fabrazyme. Acquisition to Create New Source of Growth at Sanofi With this acquisition, Sanofi is looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/12/sny-sanofi-aventis-acquires-genzyme-acquisition-to-create-new-source-of-growth-at-sanofi/71232/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire and Watson Pharmaceuticals in Patent Legal Battle</title>
		<link>http://www.stockbloghub.com/2011/04/09/shpgy-shire-and-watson-pharmaceuticals-in-patent-legal-battle/70959</link>
		<comments>http://www.stockbloghub.com/2011/04/09/shpgy-shire-and-watson-pharmaceuticals-in-patent-legal-battle/70959#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:15:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70959</guid>
		<description><![CDATA[The legal tussle between Shire (SHPGY) and Watson Pharmaceuticals Inc. (WPI) intensified with the Ireland based Shire filing a case of patent infringement and breach of contract against Watson Pharma relating to Shire’s Adderall XR. Adderall XR is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). ADHD refers to a neurobiological disorder that is often hereditary in nature. The disease gives way to lack of attention and often results in impulsiveness and hyperactivity. We note that Watson Pharma is seeking approval from the US Food and Drug Administration (FDA) to market generic versions of the ADHD drug in multiple doses before the drug’s market exclusivity expires in April 2019. To achieve the objective, Watson Pharma filed an abbreviated new drug application (ANDA) with the FDA earlier in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/shpgy-shire-and-watson-pharmaceuticals-in-patent-legal-battle/70959/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug</title>
		<link>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728</link>
		<comments>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728#comments</comments>
		<pubDate>Sat, 05 Mar 2011 00:49:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67728</guid>
		<description><![CDATA[Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase alfa. FDA Requests Additional Information The FDA asked the company to provide additional information related to clinical and chemistry, manufacturing and controls (CMC). While the agency did not ask the company to conduct additional studies, it asked Protalix to provide data from the company’s switchover and long-term extension trials. Besides this, the FDA asked the company to submit information on testing specifications and assay validation. Depending on specific requirements, the Gaucher disease candidate&#8217;s approval could get delayed by a year. The first-round approval of taliglucerase alfa would have been a major boost for Protalix, which has a strong marketing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/04/plx-protalix-biotherapeutics-sees-fda-setback-for-gaucher-drug/67728/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Quarterly Earnings Report Outperforms Expectations</title>
		<link>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018</link>
		<comments>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018#comments</comments>
		<pubDate>Wed, 16 Feb 2011 18:12:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67018</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc.&#8216;s  (WPI) fourth quarter 2010 earnings (excluding special items) of $0.93 per share were in line with the Zacks Consensus Estimate and $0.08 above the year-ago earnings. Earnings, however, dropped 70.6% to $0.15 per share on a reported basis (including special items) because of legal charges. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. Performance by Segment for the Quarter Watson Pharma&#8217;s Global Generics segment posted sales of $646 million, up 38.2%. The increase in sales was driven by contribution from new international markets, the launch of new products such as metoprolol succinate extended-release, Zarah (generic version of Bayer’s (BAYRY) Yasmin) and diltiazem extended-release. International product sales for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Protalix BioTherapeutics Seek EU Approval</title>
		<link>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746</link>
		<comments>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746#comments</comments>
		<pubDate>Tue, 21 Dec 2010 21:25:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60746</guid>
		<description><![CDATA[Pfizer (PFE) and its partner Protalix BioTherapeutics Inc. (PLX) recently announced that they have submitted the Marketing Authorization Application (MAA) for their Gaucher disease candidate in the EU. The companies are seeking marketing approval for Uplyso (taliglucerase alfa) from the European Medicines Agency. Uplyso is currently under regulatory review in the US with a response from the Food and Drug Administration (FDA) expected by Feb 25, 2011. Uplyso enjoys orphan drug status in both the EU and the US for the Gaucher disease indication. The approval of Uplyso will be a major boost for Protalix which has a strong marketing partner in Pfizer. The companies entered into a commercialization agreement in late 2009. Per the terms of the agreement, Pfizer has exclusive worldwide rights for the commercialization of Uplyso in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/21/pfe-pfizer-and-protalix-biotherapeutics-seek-eu-approval/60746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Beats Earnings Expectations &#8211; Increases Earnings Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674</link>
		<comments>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:52:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58674</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per ADS. Higher revenues accounted for the strong performance. Revenues Quarterly revenues increased 31% year over year to $874 million, well above the Zacks Consensus Estimate of $847 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 32% to $794 million, while royalties increased 27% to $76.5 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR, 3TC and Zeffix. During the third quarter, Shire received royalties from Impax Laboratories Inc. (IPXL) for Adderall XR and from GlaxoSmithKline plc (GSK) for 3TC and Zeffix. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme</title>
		<link>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301</link>
		<comments>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:29:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54301</guid>
		<description><![CDATA[French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi has launched a tender offer for all outstanding shares of Genzyme – the offer is scheduled to expire on Dec 10. Sanofi’s offer price stands at $69 per share with the entire deal being valued at $18.5 billion. The $69 offer price represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up more than 40%. Sanofi said that it launched the hostile bid mainly due to Genzyme management’s refusal to enter into constructive discussions with Sanofi. Sanofi had initially approached Genzyme with its $69 per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857</link>
		<comments>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:25:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49857</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi had announced its non-binding proposal to Genzyme with the all-cash transaction being valued at $18.5 billion. However, Genzyme’s board of directors rejected the offer calling it unrealistic. According to Genzyme, the offer price undervalues the company. The offer price of $69 per share represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up 35.6%. What Does Sanofi Gain? Sanofi has a high exposure to generic risk on many of its leading franchises. The company suffered a blow recently with the entry of a generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc Earns European Approval for Vpriv</title>
		<link>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588</link>
		<comments>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588#comments</comments>
		<pubDate>Sun, 29 Aug 2010 03:33:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49588</guid>
		<description><![CDATA[Recently, Shire Plc. (SHPGY) received a boost when the European Commission approved its Gaucher disease product Vpriv (velaglucerase alfa) for marketing in 30 European countries. The decision to approve the product does not come as a surprise as the drug’s approval for the long-term treatment of type I Gaucher disease was recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2010. Vpriv, an enzyme replacement therapy, enjoys orphan drug status from the Committee for Orphan Medical Products. Vpriv is already available in the US where it received approval from the US Food and Drug Administration in March 2010. Gaucher disease, a genetically transmitted disease, has an incidence of approximately 1 in a population of 50,000. The disorder mainly leads to the enlargement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/28/shpgy-shire-plc-earns-european-approval-for-vpriv/49588/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Drug ProAmatine&#8217;s Approval to be Withdrawn by US Food and Drug Administration</title>
		<link>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619</link>
		<comments>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:28:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48619</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension). The drug was approved under the FDA’s accelerated approval program, under which companies are required to conduct post-approval studies of the drug in order to confirm its benefits. The regulatory body noted that since the time of the approval of ProAmatine, neither Shire nor the drug’s generic makers conducted studies that proved the drug’s efficacy in patients suffering from orthostatic hypotension. Shire, in response, issued a press release saying that it had conducted post-approval trials for ProAmatine as required by the FDA, but the regulatory body found those studies inconclusive asking Shire to carry out additional trials to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/shpgy-shire-drug-proamatines-approval-to-be-withdrawn-by-us-food-and-drug-administration/48619/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Second Quarter 2010 Earnings Beat &#8211; Updates Outlook</title>
		<link>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434</link>
		<comments>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47434</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.03 per American Depositary Share (ADS) during the second quarter of 2010, beating the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 60 cents per ADS. Improved revenues accounted for the increased earnings. Revenues Quarterly revenues increased 35% year over year to $849 million, well above the Zacks Consensus Estimate of $807.5 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 37% to $764 million, while royalties increased 24% to $85 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR. Product sales include sales of Vyvanse (up 30% to $148 million), Elaprase (up 17% to $100 million), Replagal (up 84% to $82 million), Lialda (up 27% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/shpgy-shire-plc-second-quarter-2010-earnings-beat-updates-outlook/47434/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin</title>
		<link>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257</link>
		<comments>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257#comments</comments>
		<pubDate>Thu, 22 Jul 2010 02:02:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44257</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of 36 cents and the year-earlier earnings of 64 cents. Excluding the impact of stock-based compensation expense, earnings came in at 18 cents. With the company yet to emerge from manufacturing problems, we were not surprised to see the dismal second quarter results. Second quarter revenues declined 12% to $1.08 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $350.5 million, down 40%. Production and supply of two products, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/21/genz-genzyme-second-quarter-2010-earnings-miss-by-a-wide-margin/44257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire plc Hears Good News From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791</link>
		<comments>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791#comments</comments>
		<pubDate>Sun, 11 Jul 2010 14:23:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41791</guid>
		<description><![CDATA[Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The committee recommended the approval of the enzyme replacement therapy for treating type I Gaucher disease. Furthermore, the drug has been granted accelerated assessment by the EMA in the European Union (EU) and enjoys orphan drug status from the Committee for Orphan Medical Products. Shire should be in a position to launch Vpriv in the EU by year end. Meanwhile, product launch in other countries should commence in 2011. Vpriv is already available in the U.S. where it received approval from the U.S. Food and Drug Administration (FDA) in late February 2010. Vpriv Could Eat into Cerezyme’s Market ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/11/shpgy-shire-plc-hears-good-news-from-european-medicines-agency/41791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218</link>
		<comments>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218#comments</comments>
		<pubDate>Tue, 25 May 2010 03:53:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38218</guid>
		<description><![CDATA[Following the release of first quarter results on April 21, 2010, several analysts covering Genzyme Corporation (GENZ) have lowered their earnings estimates for 2010 and 2011. Genzyme is still suffering from the impact of the temporary shutdown of its Allston Landing manufacturing facility last year and has yet to resume normal supply of the key products that were affected by the shutdown. First Quarter Highlights Genzyme reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Agreement of Analysts Following the release of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/genz-genzyme-corporation-earnings-scorecard/38218/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme First Quarter Earnings Beat by a Penny</title>
		<link>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621</link>
		<comments>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621#comments</comments>
		<pubDate>Thu, 22 Apr 2010 19:57:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34621</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents. With the company facing manufacturing problems from mid-2009, we were not surprised to see first quarter revenues decline. They fell 6.5% to $1.07 billion, mainly due to restricted supplies of Cerezyme and Fabrazyme. Genzyme’s Personalized Genetic Health business (previously referred to as the Genetic Diseases business) was the most adversely affected by the temporary shutdown of the company’s Allston Landing facility in June 2009. The Personalized Genetic Health segment posted sales of $392.5 million, down 29%. Production and supply of two products, Cerezyme and Fabrazyme, were mainly affected by the temporary shutdown. While Cerezyme sales declined 39% to $179 million, Fabrazyme ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/genz-genzyme-first-quarter-earnings-beat-by-a-penny/34621/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Presents Positive Data on Vpriv</title>
		<link>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189</link>
		<comments>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189#comments</comments>
		<pubDate>Mon, 29 Mar 2010 20:09:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32189</guid>
		<description><![CDATA[Shire Plc. (SHPGY) recently presented positive phase III data on its Gaucher disease product, Vpriv. The trial was conducted to study the safety of switching patients from Genzyme’s (GENZ) Cerezyme (imiglucerase) to Vpriv. Results showed that both adult as well as pediatric patients who switched from Cerezyme to Vpriv did not develop IgG antibodies to Vpriv. This included 3 patients who tested positive for anti-Cerezyme antibodies at screening. Moreover, it was found that hemoglobin concentration, platelet counts, and liver and spleen volumes remained stable during the one year study, showing safety and maintenance of efficacy during this period. Shire also presented interim safety data from an ongoing multi-center open-label treatment protocol, which was put in place to provide Vpriv to patients affected by the shortage in supply of Cerezyme. Meanwhile, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/29/shpgy-shire-presents-positive-data-on-vpriv/32189/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely</title>
		<link>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996</link>
		<comments>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996#comments</comments>
		<pubDate>Sat, 27 Mar 2010 20:43:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31996</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period, it would also require Genzyme to make payments to the government and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/27/genz-genzyme-corporation-sees-fda-consent-decree-likely/31996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Likely to See FDA Enforcement Action</title>
		<link>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768</link>
		<comments>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768#comments</comments>
		<pubDate>Thu, 25 Mar 2010 19:53:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31768</guid>
		<description><![CDATA[Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action related to the company’s manufacturing facility at Allston Landing. The FDA has decided to adopt this course so as to ensure that the products manufactured at the Allston Landing manufacturing facility are made in compliance with good manufacturing practice regulations. It is quite likely that the agency will enforce a consent decree which means that a third party will be appointed to inspect and review the plant’s operations, and confirm compliance with FDA regulations. The consent decree will not only be in force for an extended period of time, it would also require Genzyme to make payments to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/genz-genzyme-likely-to-see-fda-enforcement-action/31768/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Hospira Inks Manufacturing Deal with Genzyme</title>
		<link>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213</link>
		<comments>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213#comments</comments>
		<pubDate>Tue, 05 Jan 2010 22:25:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24213</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) has entered into a contract manufacturing agreement with Hospira (HSP) for its key drugs Incorporatedluding Cerezyme and Fabrazyme. We believe this move has been taken to reduce the impact of the company’s manufacturing plant-related issues on the supply of its products. Any financial detail of the deal, which is set to expire in 2015, has not been disclosed. The deal has yet to receive regulatory approval for the manufacturing of these drugs. Genzyme has been under significant pressure following the shutdown of its Allston manufacturing facility in June 2009. The shutdown is a major setback as three drugs Incorporatedluding Cerezyme, were being manufactured at the facility. The closure of the plant has affected Genzyme’s financial performance significantly with third quarter revenues declining 9% to $1.06 billion. Last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/05/genz-hospira-inks-manufacturing-deal-with-genzyme/24213/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Seeks U.S. Food and Drug Administration Approval</title>
		<link>http://www.stockbloghub.com/2009/12/28/shpgy-shire-seeks-u-s-food-and-drug-administration-approval/23736</link>
		<comments>http://www.stockbloghub.com/2009/12/28/shpgy-shire-seeks-u-s-food-and-drug-administration-approval/23736#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:14:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23736</guid>
		<description><![CDATA[Shire Plc (SHPGY) recently submitted a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for Replagal (agalsidase alfa) meant for treating the genetic disorder Fabry disease. Replagal is available in European markets since 2001.The drug is approved for the treatment of Fabry disease in 45 countries. In the United States, the drug is available to Fabry patients under an FDA-approved treatment protocol, and the company is also supporting emergency Investigational New Drug (IND) requests. The shortage of Genzyme Corp.’s (GENZ) Fabrazyme, arising out of the manufacturing problems at a key Genzyme facility has prompted the FDA to allow Replagel to be supplied to certain patients in the U.S. Shire is seeking full approval through the current BLA submission. Fabry disease is a genetic disorder that interferes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/shpgy-shire-seeks-u-s-food-and-drug-administration-approval/23736/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PLX) Protalix Biotherapeutics&#8217; Drug Advances</title>
		<link>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576</link>
		<comments>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576#comments</comments>
		<pubDate>Fri, 11 Dec 2009 13:35:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22576</guid>
		<description><![CDATA[Good news for Protalix Biotherapeutics (PLX) once again! The company completed the submission of its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for taliglucerase alfa, which is meant for the treatment of Gaucher disease. It has been granted orphan-drug designation and fast-track status by the FDA to facilitate its development. Taliglucerase alfa is currently being given to patients suffering from Gaucher disease in the US and the European Union under the Expanded Access Program and compassionate use protocol, respectively. Earlier this month, the company entered into an agreement with Pfizer (PFE) related to the development and commercialization of this drug. As per the deal, Pfizer will have exclusive worldwide licensing rights to commercialize taliglucerase alfa while Protalix has retained its commercialization rights in Israel. Under ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/plx-protalix-biotherapeutics-drug-advances/22576/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Bayer Advances on Alzheimer&#8217;s Plan</title>
		<link>http://www.stockbloghub.com/2009/12/04/pfe-bayer-advances-on-alzheimers-plan/22021</link>
		<comments>http://www.stockbloghub.com/2009/12/04/pfe-bayer-advances-on-alzheimers-plan/22021#comments</comments>
		<pubDate>Sat, 05 Dec 2009 02:00:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22021</guid>
		<description><![CDATA[Alzheimer’s disease (AD) is a devastating neuro-degenerative disease that affects people over the age of 60. The onset of the disease is often so gradual and the early signs are so mild that they are often mistaken as common traits of ageing. Early detection of the disease is significant as many of the available treatment options are most effective in the early stages. However, there is no such detection test available currently although some are under trial. The situation may change completely if Bayer (BAYRY) accomplishes its objective. The company recently decided to go ahead with the development of florbetaben to support the proper diagnosis of AD. At the recently held 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer announced the enrollment of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/pfe-bayer-advances-on-alzheimers-plan/22021/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Resumes Cerezyme Shipment</title>
		<link>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850</link>
		<comments>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850#comments</comments>
		<pubDate>Thu, 03 Dec 2009 22:45:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21850</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently reported progress on the resumption of supply of new lots of Cerezyme from its Allston Landing manufacturing facility, which was temporarily shut down due to contamination issues. The company announced that it has started shipping vials of the newly produced Cerezyme. The initial lot of the Cerezyme shipment will be used to provide uninterrupted treatment to the most vulnerable patients. By the end of Dec, the company expects to expand supply so as to cover those patients who had experienced interruptions in treatment due to the shortage in supply. Genzyme believes it will be able to meet worldwide demand for the product in the first quarter of 2010. Genzyme also provided an update on the resumption of supply of Fabrazyme, indicated for Fabry disease, which was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/03/genz-genzyme-resumes-cerezyme-shipment/21850/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Plc&#8217;s Drug Seeks European Medicines Agency Approval</title>
		<link>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289</link>
		<comments>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:10:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21289</guid>
		<description><![CDATA[Shire plc (SHPGY) continues to make progress with its Gaucher disease candidate, velaglucerase alfa. The company recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for velaglucerase alfa for the treatment of type I Gaucher disease. The company has already asked for approval in other markets like the U.S. and Canada. Shire is seeking an accelerated review of the MAA. Given the shortage in supply of Genzyme’s (GENZ) Cerezyme, which is the leader in the treatment of patients with Gaucher disease, the Committee for Medicinal Products for Human Use (CHMP) has accepted Shire’s request. Accordingly, the review time has been reduced by 60 days to 150 days with the review scheduled to commence in December. Once approved and launched commercially, velaglucerase alfa will compete directly with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/shpgy-shire-plcs-drug-seeks-european-medicines-agency-approval/21289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation&#8217;s Problems Continue</title>
		<link>http://www.stockbloghub.com/2009/11/19/genz-genzyme-corporations-problems-continue/20939</link>
		<comments>http://www.stockbloghub.com/2009/11/19/genz-genzyme-corporations-problems-continue/20939#comments</comments>
		<pubDate>Thu, 19 Nov 2009 20:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20939</guid>
		<description><![CDATA[Genzyme Corporation’s (GENZ) problems continue with the company recently announcing the discontinuation of the development of its kidney disease drug. Genzyme reported results on its advanced phosphate binder (APB) from a phase II/III study. Although the candidate met its primary endpoint, results showed that it was not more effective than Renvela, a product that is marketed by Genzyme. Based on these results, the company has decided to discontinue further clinical development of the APB. Genzyme was looking to develop a product with higher potency that would more effectively bind phosphate, while maintaining all the benefits of Renvela. Renvela is a follow-on product of the company’s kidney disease drug, Renagel. Sales of Renagel/Renvela totaled $677.7 million or 15% of total revenue in 2008. Renagel and Renvela are phosphate binders for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/19/genz-genzyme-corporations-problems-continue/20939/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corp Haunted by Contamination Issues</title>
		<link>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699</link>
		<comments>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699#comments</comments>
		<pubDate>Tue, 17 Nov 2009 01:03:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20699</guid>
		<description><![CDATA[Biotech company Genzyme Corp. (GENZ), faced yet another setback recently when the U.S. Food and Drug Administration (FDA) announced that vials of five drugs marketed by the company were found to be contaminated. The affected drugs include Cerezyme, Myozyme, Fabrazyme, Aldurazyme and Thyrogen. All these drugs, excluding Thyrogen, are indicated for the treatment of rare disorders. The vials were found to be contaminated with stainless steel fragments, non-latex rubber from the vial stopper, and fiber-like material from the manufacturing process which could potentially harm patients. As adverse events are yet to be reported and given the lack of alternative treatments for these drugs which treat rare disorders, the FDA did not issue a product recall. Instead, Genzyme has issued letters to U.S. healthcare providers reminding them to conduct a visual ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/16/genz-genzyme-corp-haunted-by-contamination-issues/20699/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Misses &amp; Slashes Earnings Guidance Again for 2009</title>
		<link>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392</link>
		<comments>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:07:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18392</guid>
		<description><![CDATA[This morning, Genzyme Corp (GENZ) reported third quarter earnings of 19 cents per share, which was well below the Zacks Consensus Estimate of 31 cents and the year ago earnings of 93 cents. Moreover, revenues declined 9% to $1.06 billion. As expected, the temporary shutdown of the company’s Allston manufacturing facility earlier this year impacted overall financial results. Although the company has resumed production at this facility, the temporary shutdown led to a disruption in the supply of key products Cerezyme and Fabrazyme. Cerezyme’s performance was highly affected with sales dropping 69.7% to $93.6 million in the reported quarter. Fabrazyme sales came in at $115.2 million, down 8% from the prior-year quarter. Genzyme expects to resume supply of new lots of Cerezyme and Fabrazyme from late November and late December, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/genz-genzyme-misses-slashes-earnings-guidance-again-for-2009/18392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Struggles to Restore Order</title>
		<link>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092</link>
		<comments>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092#comments</comments>
		<pubDate>Sat, 26 Sep 2009 21:06:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16092</guid>
		<description><![CDATA[On Wednesday, Genzyme Corp. (GENZ) provided a mixed update on its supply schedule for Cerezyme and Fabrazyme. The two key contributors to the company’s top line are produced at its Allston plant. Last June, Genzyme had to temporarily shut down this unit due to contamination issues. While we were pleased to hear that Cerezyme production is on track and new batches of the product will be available for shipment in the November-December timeframe, we were disappointed to hear that new lots of Fabrazyme will not be available for shipment till mid-December. Moreover, the volume of finished products of Fabrazyme will be lower than expected. The company said that Fabrazyme bioreactors were restarted later than planned and output from the two bioreactors is expected to be lower. We believe the delay ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/26/genz-genzyme-struggles-to-restore-order/16092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916</link>
		<comments>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:42:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALTU]]></category>
		<category><![CDATA[Altus Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15916</guid>
		<description><![CDATA[Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to evaluate the effect of PEG-PAL on blood phenylalanine (Phe) concentrations in PKU patients. The secondary objectives are to evaluate its safety and tolerability, immune response and steady state pharmacokinetics of subcutaneous injections of multiple dose levels. BioMarin, which competes with companies such as Enzon Pharmaceuticals Inc. (ENZN), Shire Plc (SHPGY) and Altus Pharmaceuticals Inc. (ALTU), already has Kuvan in the market for treating PKU. The primary difference between PEG-PAL and Kuvan is the mode ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Receives FDA Approval for Intuniv</title>
		<link>http://www.stockbloghub.com/2009/09/04/shpgy-shire-receives-fda-approval-for-intuniv/14474</link>
		<comments>http://www.stockbloghub.com/2009/09/04/shpgy-shire-receives-fda-approval-for-intuniv/14474#comments</comments>
		<pubDate>Fri, 04 Sep 2009 23:10:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14474</guid>
		<description><![CDATA[We are pleased to hear that yesterday, the US Food and Drug Administration (FDA) has approved Shire Plc’s (SHPGY) Intuniv (guanfacine) extended release tablets. The drug is for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years. The drug, in four dosage strengths (1 mg, 2 mg, 3 mg and 4 mg) is expected to be available in the US from November. Although the Prescription Drug User Fee Act (PDUFA) date for Intuniv was July 27, 2009, the approval was delayed as Shire and the FDA were unable to reach an agreement on final product labeling. With the introduction of Intuniv, Shire is intending to expand and diversify its ADHD portfolio. Apart from Intuniv, Shire now has Daytrana, Equasym, Vyvanse, Adderall XR as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/04/shpgy-shire-receives-fda-approval-for-intuniv/14474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Moving Up with Gaucher Drug</title>
		<link>http://www.stockbloghub.com/2009/09/02/shpgy-shire-moving-up-with-gaucher-drug/14277</link>
		<comments>http://www.stockbloghub.com/2009/09/02/shpgy-shire-moving-up-with-gaucher-drug/14277#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:24:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14277</guid>
		<description><![CDATA[Yesterday, Shire plc (SHPGY) submitted its new drug application (NDA) for velaglucerase alfa, its enzyme replacement therapy for the treatment of type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). Shire also announced that velaglucerase alfa achieved its primary and secondary endpoints in all three of its phase III studies Incorporatedluding a head-to-head study with Genzyme Corp.’s (GENZ) Cerezyme. Another study, assessing the safety of switching patients from Cerezyme therapy to velaglucerase alfa, also posted positive results. We were pleased to see Shire submit the NDA slightly ahead of schedule. The European submission is scheduled to take place by year&#8217;s end. Once approved and launched commercially, velaglucerase alfa will compete directly with Cerezyme. Shire is currently providing the treatment free of cost to patients. As a reminder, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/shpgy-shire-moving-up-with-gaucher-drug/14277/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Another Blow for Genzyme</title>
		<link>http://www.stockbloghub.com/2009/08/26/genz-another-blow-for-genzyme/13514</link>
		<comments>http://www.stockbloghub.com/2009/08/26/genz-another-blow-for-genzyme/13514#comments</comments>
		<pubDate>Wed, 26 Aug 2009 21:05:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13514</guid>
		<description><![CDATA[Yesterday, Protalix BioTherapeutics Inc., a potential competitor for Genzyme Corp.’s (GENZ) lead product Cerezyme, announced that the US Food and Drug Administration (FDA) had granted its pipeline candidate prGCD a fast-track status. prGCD is an enzyme replacement therapy for the treatment of Gaucher disease. Protalix plans to complete the submission of its new drug application (NDA) for prGCD by year-end. Late-stage data on prGCD should be out in October. Earlier this month, Genzyme suffered a setback when the FDA approved treatment protocols for two potential rivals &#8211; prGCD and Shire Pharma’s (SHPGY) velaglucerase alfa. The FDA had asked both companies to consider submitting a treatment protocol that would enable the use of their Gaucher drugs in an expanded-access program to make up for a shortage in supply of Cerezyme, which is the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/genz-another-blow-for-genzyme/13514/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Aims Big in Human Genetic Therapies Business Segment</title>
		<link>http://www.stockbloghub.com/2009/08/26/shpgy-cns-shire-aims-big-in-hgt-segment/13419</link>
		<comments>http://www.stockbloghub.com/2009/08/26/shpgy-cns-shire-aims-big-in-hgt-segment/13419#comments</comments>
		<pubDate>Wed, 26 Aug 2009 15:36:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13419</guid>
		<description><![CDATA[We are pleased with UK-based Shire Plc’s (SHPGY) research collaboration with Denmark’s Santaris Pharma for the development of new drugs for rare diseases. Shire will make an upfront payment of $6.5 million and an additional $13.5 million on completion of certain initial studies. Santaris Pharma also has the potential to get another $72 million in the form of development, regulatory and sales-related milestone payments for each of its five pipeline candidates along with royalties on sales once these products are commercialized. The initial term of the collaboration is two years and Shire may extend it by another two-year term. With this deal, Shire will be able to utilize Santaris&#8217; proprietary locked nucleic acid (LNA) technology platform to develop treatments for several life threatening conditions that cannot be cured by enzyme ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/shpgy-cns-shire-aims-big-in-hgt-segment/13419/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

